The prevalence of WD is estimated at 1 in 30,000, and the heterozygous carrier rate is close to 1 in 90 in many populations.[9,10] Early diagnosis and treatment are critical for preventing disease progression and irreversible sequelae.[11] Genetic testing of ATP7B is a reliable tool for diagnosing WD, especially for early onset. Here, ATP7B is linked to Wilson disease.